RCM

RA Capital Management Portfolio holdings

AUM $5.94B
This Quarter Return
+1.05%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$6.63B
AUM Growth
+$6.63B
Cap. Flow
-$82.7M
Cap. Flow %
-1.25%
Top 10 Hldgs %
50.25%
Holding
100
New
18
Increased
9
Reduced
13
Closed
18

Top Buys

1
VOR icon
Vor Biopharma
VOR
$479M
2
TIL icon
Instil Bio
TIL
$122M
3
EWTX icon
Edgewise Therapeutics
EWTX
$84.9M
4
BOLT icon
Bolt Biotherapeutics
BOLT
$78.3M
5
MCRB icon
Seres Therapeutics
MCRB
$76.1M

Top Sells

1
ARVN icon
Arvinas
ARVN
$312M
2
TGTX icon
TG Therapeutics
TGTX
$195M
3
NVAX icon
Novavax
NVAX
$143M
4
KROS icon
Keros Therapeutics
KROS
$132M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
$72.9M

Sector Composition

1 Healthcare 95.53%
2 Financials 0.47%
Name Market Value Portfolio Weight Shares or Principal Shares
Change % 		Capital Flow
MLTX icon
76
MoonLake Immunotherapeutics
MLTX
$3.78B
$7.15M 0.11%
700,000
– –
OBIO icon
77
Orchestra BioMed
OBIO
$147M
$6.99M 0.11%
625,000
– –
SYRS
78
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$6.73M 0.1%
+900,000
New +$6.73M
VRDN icon
79
Viridian Therapeutics
VRDN
$1.59B
$5.22M 0.08%
312,328
-139,604
-31% -$2.33M
XFOR icon
80
X4 Pharmaceuticals
XFOR
$70M
$4.62M 0.07%
536,962
– –
ELVN icon
81
Enliven Therapeutics
ELVN
$1.24B
$2.1M 0.03%
248,804
– –
CEREW
82
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$1.01M 0.02%
233,333
– –
INBX
83
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-2,129,003
Closed -$70.2M
PAND
84
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
– –
-1,770,023
Closed -$26.3M
FPRX
85
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-4,285,161
Closed -$72.9M
MRNS
86
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-1,300,000
Closed -$15.9M
VXRT
87
DELISTED
Vaxart
VXRT
– –
-2,742,271
Closed -$15.7M
PROF
88
Profound Medical
PROF
$131M
– –
-192,311
Closed -$3.95M
PASG icon
89
Passage Bio
PASG
$22.7M
– –
-322,630
Closed -$8.25M
PACB icon
90
Pacific Biosciences
PACB
$378M
– –
-1,987,997
Closed -$51.6M
OVID icon
91
Ovid Therapeutics
OVID
$94.6M
– –
-285,000
Closed -$658K
LYRA icon
92
Lyra Therapeutics
LYRA
$11.8M
– –
-815,849
Closed -$9.3M
LEGN icon
93
Legend Biotech
LEGN
$6.64B
– –
-2,408,292
Closed -$67.8M
KROS icon
94
Keros Therapeutics
KROS
$640M
– –
-1,875,000
Closed -$132M
CRNX icon
95
Crinetics Pharmaceuticals
CRNX
$3.26B
– –
-564,102
Closed -$7.96M
CRDF icon
96
Cardiff Oncology
CRDF
$130M
– –
-3,290,000
Closed -$59.2M
ARVN icon
97
Arvinas
ARVN
$580M
– –
-3,672,872
Closed -$312M
ARQT icon
98
Arcutis Biotherapeutics
ARQT
$1.91B
– –
-1,165,184
Closed -$32.8M
ALEC icon
99
Alector
ALEC
$282M
– –
-1,616,879
Closed -$24.5M
ADAP
100
Adaptimmune Therapeutics
ADAP
$13.9M
– –
-2,499,025
Closed -$13.5M
1 2 3
4